These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. The pharmacology and clinical pharmacology of defibrotide: a new profibrinolytic, antithrombotic and anti-platelet substance. Ulutin ON, Balkuv-Ulutin S, Ugur MS, Ulutin T, Ozsoy Y, Cizmeci G. Adv Exp Med Biol; 1990 Jan; 281():429-38. PubMed ID: 2102624 [Abstract] [Full Text] [Related]
13. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Palmer KJ, Goa KL. Drugs; 1993 Feb; 45(2):259-94. PubMed ID: 7681375 [Abstract] [Full Text] [Related]
18. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide. Ulutin ON, Cizmeci G, Balkuv-Ulutin S. Folia Haematol Int Mag Klin Morphol Blutforsch; 1988 Dec 01; 115(1-2):177-80. PubMed ID: 2459016 [Abstract] [Full Text] [Related]
20. In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 alpha in humans in response to a standardized vascular injury and the influence of aspirin. Gerrard JM, Taback S, Singhroy S, Docherty JC, Kostolansky I, McNicol A, Kobrinsky NL, McKenzie JK, Rowe R. Circulation; 1989 Jan 01; 79(1):29-38. PubMed ID: 2910545 [Abstract] [Full Text] [Related] Page: [Next] [New Search]